

Takeki Uehara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5197786/publications.pdf>

Version: 2024-02-01

59
papers

2,971
citations

201575

27
h-index

168321

53
g-index

59
all docs

59
docs citations

59
times ranked

3448
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. <i>PLoS Pathogens</i> , 2021, 17, e1009527.	2.1	23
2	The DEN and CCL4-Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. <i>Current Protocols</i> , 2021, 1, e211.	1.3	7
3	Open-label study of the safety, pharmacokinetics, and effectiveness of a 2Âmg/kg dose of baloxavir marboxil 2% granules in children <20Âkg with influenza. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1223-1229.	0.8	1
4	Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 477-484.	0.6	6
5	Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. <i>Journal of Infectious Diseases</i> , 2020, 221, 346-355.	1.9	104
6	Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 71, 971-981.	2.9	99
7	A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 87-101.	1.4	8
8	Baloxavir Marboxil 2% Granules in Japanese Children With Influenza. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 706-712.	1.1	12
9	Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1204-1214.	4.6	134
10	Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. <i>New England Journal of Medicine</i> , 2020, 383, 309-320.	13.9	93
11	Comment to: Baloxavir efficacy in North American Adults. <i>European Journal of Internal Medicine</i> , 2020, 72, 99-101.	1.0	0
12	Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 353-357.	1.5	1
13	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. <i>PLoS Pathogens</i> , 2020, 16, e1008395.	2.1	28
14	Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. <i>Antiviral Research</i> , 2019, 163, 75-81.	1.9	22
15	Histopathological and Molecular Signatures of a Mouse Model of Acute-on-Chronic Alcoholic Liver Injury Demonstrate Concordance With Human Alcoholic Hepatitis. <i>Toxicological Sciences</i> , 2019, 170, 427-437.	1.4	15
16	Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. <i>New England Journal of Medicine</i> , 2018, 379, 913-923.	13.9	629
17	Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. <i>Scientific Reports</i> , 2018, 8, 9633.	1.6	306
18	Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse. <i>Toxicology and Applied Pharmacology</i> , 2018, 339, 1-9.	1.3	32

#	ARTICLE	IF	CITATIONS
19	Differentially expressed MicroRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice. <i>Molecular Carcinogenesis</i> , 2016, 55, 808-817.	1.3	11
20	Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease. <i>Cancer Medicine</i> , 2016, 5, 574-585.	1.3	6
21	A mouse model of alcoholic liver fibrosis-associated acute kidney injury identifies key molecular pathways. <i>Toxicology and Applied Pharmacology</i> , 2016, 310, 129-139.	1.3	14
22	Diagnostic and predictive performance and standardized threshold of traditional biomarkers for drug-induced liver injury in rats. <i>Journal of Applied Toxicology</i> , 2015, 35, 165-172.	1.4	10
23	Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. <i>Journal of Applied Toxicology</i> , 2015, 35, 173-180.	1.4	77
24	Combinatorial Measurement of CDKN1A/p21 and KIF20A Expression for Discrimination of DNA Damage-Induced Clastogenicity. <i>International Journal of Molecular Sciences</i> , 2014, 15, 17256-17269.	1.8	7
25	Identification of metabolomic biomarkers for drug-induced acute kidney injury in rats. <i>Journal of Applied Toxicology</i> , 2014, 34, 1087-1095.	1.4	41
26	Comparative gene and protein expression analyses of a panel of cytokines in acute and chronic drug-induced liver injury in rats. <i>Toxicology</i> , 2014, 324, 43-54.	2.0	11
27	Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. <i>International Journal of Cancer</i> , 2014, 134, 2778-2788.	2.3	39
28	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. <i>Toxicology</i> , 2014, 315, 8-16.	2.0	15
29	Detection of initiating potential of non-genotoxic carcinogens in a two-stage hepatocarcinogenesis study in rats. <i>Journal of Toxicological Sciences</i> , 2014, 39, 785-794.	0.7	15
30	Comprehensive analysis of DNA methylation and gene expression of rat liver in a 2-stage hepatocarcinogenesis model. <i>Journal of Toxicological Sciences</i> , 2014, 39, 837-848.	0.7	3
31	Toxicogenomics discrimination of potential hepatocarcinogenicity of non-genotoxic compounds in rat liver. <i>Journal of Applied Toxicology</i> , 2013, 33, 1284-1293.	1.4	25
32	Molecular Mechanisms of Fibrosis-Associated Promotion of Liver Carcinogenesis. <i>Toxicological Sciences</i> , 2013, 132, 53-63.	1.4	84
33	Toxicogenomic biomarkers for renal papillary injury in rats. <i>Toxicology</i> , 2013, 303, 1-8.	2.0	17
34	Acetaminophen-induced acute liver injury in HCV transgenic mice. <i>Toxicology and Applied Pharmacology</i> , 2013, 266, 224-232.	1.3	10
35	Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies. <i>Journal of Applied Toxicology</i> , 2013, 33, 1120-1130.	1.4	14
36	Predictive genomic biomarkers for drug-induced nephrotoxicity in mice. <i>Journal of Toxicological Sciences</i> , 2012, 37, 723-737.	0.7	19

#	ARTICLE	IF	CITATIONS
37	Toxicogenomic multigene biomarker for predicting the future onset of proximal tubular injury in rats. <i>Toxicology</i> , 2012, 297, 47-56.	2.0	41
38	Predicting Drug-Induced Hepatotoxicity Using QSAR and Toxicogenomics Approaches. <i>Chemical Research in Toxicology</i> , 2011, 24, 1251-1262.	1.7	190
39	Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. <i>Toxicology and Applied Pharmacology</i> , 2011, 255, 297-306.	1.3	92
40	Decrease in urinary creatinine in acute kidney injury influences diagnostic value of urinary biomarker-to-creatinine ratio in rats. <i>Toxicology</i> , 2011, 290, 241-248.	2.0	24
41	A toxicogenomic approach for identifying biomarkers for myelosuppressive anemia in rats. <i>Toxicology</i> , 2011, 282, 139-145.	2.0	8
42	Interstrain Differences in the Liver Effects of Trichloroethylene in a Multistrain Panel of Inbred Mice. <i>Toxicological Sciences</i> , 2011, 120, 206-217.	1.4	49
43	Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and Histopathological Characteristics. <i>Journal of Toxicologic Pathology</i> , 2011, 24, 87-94.	0.3	43
44	Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. <i>Toxicology</i> , 2010, 273, 53-59.	2.0	75
45	Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats. <i>Toxicology</i> , 2010, 271, 36-44.	2.0	28
46	Mechanism for Prevention of Alcohol-Induced Liver Injury by Dietary Methyl Donors. <i>Toxicological Sciences</i> , 2010, 115, 131-139.	1.4	29
47	Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database. <i>Toxicology</i> , 2009, 265, 15-26.	2.0	63
48	Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. <i>Toxicology</i> , 2009, 266, 48-54.	2.0	58
49	Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy. <i>Journal of Toxicological Sciences</i> , 2009, 34, 281-293.	0.7	30
50	A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. <i>Toxicology</i> , 2008, 250, 15-26.	2.0	109
51	Gene expression profiling of methapyrilene-induced hepatotoxicity in rat. <i>Journal of Toxicological Sciences</i> , 2008, 33, 37-50.	0.7	32
52	Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats. <i>Human and Experimental Toxicology</i> , 2007, 26, 767-780.	1.1	23
53	GENE EXPRESSION PROFILING OF RAT LIVER TREATED WITH SERUM TRIGLYCERIDE-DECREASING COMPOUNDS. <i>Journal of Toxicological Sciences</i> , 2007, 32, 387-399.	0.7	14
54	IDENTIFICATION OF GLUTATHIONE DEPLETION-RESPONSIVE GENES USING PHORONE-TREATED RAT LIVER. <i>Journal of Toxicological Sciences</i> , 2007, 32, 469-486.	0.7	30

#	ARTICLE	IF	CITATIONS
55	Amelioration of Nedaplatin-Induced Nephrotoxicity by Continuous Infusion in Rats. Journal of Toxicologic Pathology, 2007, 20, 141-147.	0.3	4
56	UTILIZATION OF A ONE-DIMENSIONAL SCORE FOR SURVEYING CHEMICAL-INDUCED CHANGES IN EXPRESSION LEVELS OF MULTIPLE BIOMARKER GENE SETS USING A LARGE-SCALE TOXICOGENOMICS DATABASE. Journal of Toxicological Sciences, 2006, 31, 433-448.	0.7	34
57	Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Archives of Toxicology, 2005, 79, 451-460.	1.9	47
58	Heterogeneous Liver Lobe Responses of Carbon Tetrachloride-Induced Hepatotoxicity in Male Rats Pretreated with Hepatic Enzyme-Inducing Agents. Journal of Toxicologic Pathology, 2004, 17, 223-230.	0.3	2
59	Susceptibility of Liver Proliferative Lesions in Heterozygous p53 Deficient CBA Mice to Various Carcinogens.. Journal of Veterinary Medical Science, 2002, 64, 551-556.	0.3	8